Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective Randomized Trial Comparing Transcatheter Arterial Chemoembolization (TACE) Followed by Sorafenib Versus TACE Alone for Advanced Hepatocellular Carcinoma

NCT02150317 is registered in ClinicalTrials.gov with Eastern Hepatobiliary Surgery Hospital as lead sponsor.

NCT NCT02150317
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02150317 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective Randomized Trial Comparing Transcatheter Arterial Chemoembolization (TACE) Followed by Sorafenib Versus TACE Alone for Advanced Hepatocellular Carcinoma
Lead sponsor
Eastern Hepatobiliary Surgery Hospital
Phase
Not applicable
Overall status
Unknown status
Start date
January 31, 2014
Completion date
December 31, 2016
Enrollment
180 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

advanced hepatocellular carcinoma